Floatz logo

IBUPROFEN

Relapsing Multiple Sclerosis

Genzyme, a Sanofi CompanySmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
81/ 100

Competitive context

80 Active assets in the Relapsing Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
ibuprofen intoxication, non-human animalDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →